Bimatoprost: Prostaglandin Analogue in Glaucoma and Eyelash Hypotrichosis
Bimatoprost is a synthetic prostaglandin F2alpha analogue that has been used in ophthalmology since 2002 to reduce elevated intraocular pressure in open-angle glaucoma and ocular hypertension. It is primarily known under the brand names Lumigan (eye drops) and Latisse (US market) or Ganfort (combination product with timolol). A second, cosmetically motivated indication is eyelash hypotrichosis, where bimatoprost as a topical solution promotes eyelash growth in length, density, and pigmentation.
The substance is part of first-line glaucoma therapy because it effectively reduces intraocular pressure and is well tolerated. Once-daily application improves compliance, which is particularly important for a chronic, asymptomatic disease such as glaucoma. Glaucoma is the second most common cause of blindness worldwide; in Germany, approximately one million people are affected, although many are undiagnosed.
Mechanism of Action
Bimatoprost is a prostamide, a variant of prostaglandin F2alpha. After topical application, it is hydrolyzed to free acid in the cornea, which then binds to the FP prostaglandin receptor in the trabecular meshwork and in the uveoscleral drainage system. The main effect is an enhancement of uveoscleral aqueous humor outflow, which is the secondary drainage pathway, as well as, to a lesser extent, an improvement in trabecular outflow.
In glaucoma, intraocular pressure is elevated because either aqueous humor production is too high or drainage is impaired. Chronic pressure elevation damages optic nerve fibers at the optic disc and leads to typical visual field defects. Bimatoprost reduces intraocular pressure (IOP) by approximately 25 to 33 percent, comparable to other prostaglandin analogues and more effective than timolol or brimonidine in most studies.
The effect on eyelash growth is explained by prolongation of the anagen phase in the hair cycle and stimulation of melanocytes. This pleiotropic effect was initially observed as a side effect in glaucoma patients and later developed cosmetically.
Indications
- Primary Open-Angle Glaucoma (POAG): First-line therapy for reducing intraocular pressure
- Ocular Hypertension: Pressure reduction to prevent glaucoma progression
- Pigment Dispersion Glaucoma, Pseudoexfoliation Glaucoma: Secondary glaucoma forms with elevated IOP
- Eyelash Hypotrichosis: Cosmetic indication, approved in the USA, in Europe as off-label use or via cosmeceuticals
- Combination Therapy for insufficient pressure reduction with monotherapy, often in fixed combinations with timolol
Dosage and Administration
Glaucoma: One drop of bimatoprost 0.01% or 0.03% into the conjunctival sac of the affected eye once daily, preferably in the evening. More frequent application does not enhance the effect and may even reduce it (tachyphylaxis).
Eyelash Solution: Once daily in the evening, apply one drop along the upper eyelid margin with a sterile applicator. Visible effects after eight to twelve weeks, full effect after 16 weeks. After discontinuation, eyelash growth returns to baseline status within a few months.
Application Tips: Remove contact lenses before instillation and reinsert after 15 minutes. After instillation, gently compress the tear ducts at the inner corner of the eye to reduce systemic absorption and taste disturbances. Apply multiple eye drops with an interval of at least five minutes.
Adverse Effects
Very Common: Conjunctival hyperemia (eye redness), especially pronounced in the first weeks; eyelash growth, elongation and thickening; pruritus, mild foreign body sensation, dry eyes.
Common: Iris pigmentation with increased browning of the iris, especially in mixed-color irises (irreversible); periocular hyperpigmentation of eyelid skin; deepening of the upper lid sulcus due to periorbital lipoatrophy (PAP, prostaglandin-associated periorbitopathy).
Occasional to Rare: Cystoid macular edema (especially in pseudophakia and aphakia), reactivation of herpes simplex keratitis, uveitis, asthma exacerbation in patients with bronchial hyperresponsiveness, headaches.
Important, Cosmetic Effects: Patients must be informed before starting therapy about possible permanent changes in eye color and periorbital region, as these may be irreversible.
Drug Interactions
- Other Prostaglandin Analogues (Latanoprost, Travoprost): No additive benefit with combination, rather competing effects
- Timolol and Other Beta-Blockers at the Eye: Additive IOP reduction, sensible as combination therapy (Ganfort, Combigan)
- Pilocarpine: Both reduce IOP, clinically well tolerated
- Systemic Beta-Blockers: Additive effect with topical beta-blockers, special caution in asthma and heart failure
- Brimonidine (Alpha 2 Agonist): Additive, often combination therapy
Special Notes
Pregnancy and Breastfeeding: Bimatoprost is not recommended for use during pregnancy because prostaglandins can theoretically trigger labor. During breastfeeding, insufficient data are available; the risk to the infant is considered low, but specialist medical evaluation is required.
Contact Lenses: Most bimatoprost products contain benzalkonium chloride as a preservative, which is absorbed by soft contact lenses. Remove lenses before instillation and reinsert after 15 minutes. Preservative-free single-dose preparations are an alternative for dry eyes or intolerance.
Therapy Adherence: Glaucoma is asymptomatic, and many patients fail to continue therapy. This non-compliance is the most common cause of optic nerve damage despite ongoing treatment. Reminder systems, fixed combinations with fewer drops, and comprehensive patient education improve adherence.
Switching After Insufficient Response: If IOP is not sufficiently reduced after four to six weeks, switching to another prostaglandin analogue or adding a second mechanism of action may be considered. If pressure control remains inadequate, laser therapy (SLT) and surgical procedures are available.
You May Also Be Interested In
- Latanoprost, another prostaglandin analogue
- Timolol, beta-blocker for IOP reduction
- Brimonidine, alpha 2 agonist
- Dorzolamide, carbonic anhydrase inhibitor
- Pilocarpine, cholinergic agent at the eye
Frequently Asked Questions
Will my eyes really turn brown from bimatoprost?
With mixed-color irises (green-brown, blue-brown, hazel), pigmentation can permanently change by stimulating melanocytes in the iris. In purely blue or purely brown eyes, the effect is rare or barely noticeable. The change is slow, painless, and usually not reversible after discontinuation. The ophthalmologist will inform you about this before starting therapy.
When should I apply the eye drops?
Ideally once in the evening. More frequent application does not increase the effect and may even reduce it. If additional eye drops are needed, maintain an interval of at least five minutes and apply the active prostaglandin last.
Can I grow my eyelashes with bimatoprost?
In the USA, a cosmetic bimatoprost solution (Latisse) is approved; in Europe, it is not. The effect is real but limited: eyelashes become longer, denser, and darker, but return to baseline after discontinuation. Possible side effects such as periocular hyperpigmentation and eye irritation should be considered; medical consultation is advisable.
What to do about red eyes from bimatoprost?
Conjunctival hyperemia is common in the first few weeks and usually mild. With more severe or persistent redness, inform the ophthalmologist; a preservative-free variant or another product may be prescribed. Tachyphylaxis after several weeks is common.
Sources
- EMA, Lumigan (Bimatoprost) EPAR
- German Ophthalmological Society, Glaucoma Guidelines
- Gelbe Liste, Bimatoprost Drug Profile
- BfArM, Federal Institute for Drugs and Medical Devices
Legal Information and Disclaimer
The information provided on this page is for general information purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medicines should only be taken as prescribed by a physician or dispensed by a pharmacy. All information is based on expert information and recognized scientific sources published at the time of creation; the current product information from the manufacturer is authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In a medical emergency, call emergency number 112.